xalkori
(CRIZOTINIB)Pfizer Laboratories Div Pfizer Inc
Usage: XALKORI is indicated for adults and pediatric patients aged 1 year and older with metastatic non-small cell lung cancer (NSCLC) that is ALK or ROS1-positive, as well as relapsed or refractory systemic ALK-positive anaplastic large cell lymphoma (ALCL), and unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors.